目的建立重组Omicron BA.4/5-Delta株新冠疫苗体外相对效力的检测方法,并进行验证,以期为替代体内效力检测奠定基础。方法以人源单克隆抗体GH4作为包被抗体,HRP标记的CB6人源单克隆抗体作为酶标抗体的双抗体夹心ELISA法为基础,确定疫苗...目的建立重组Omicron BA.4/5-Delta株新冠疫苗体外相对效力的检测方法,并进行验证,以期为替代体内效力检测奠定基础。方法以人源单克隆抗体GH4作为包被抗体,HRP标记的CB6人源单克隆抗体作为酶标抗体的双抗体夹心ELISA法为基础,确定疫苗解吸附方法;再以该解吸附方法结合双抗体夹心ELISA法建立体外相对效力检测方法。并验证方法的线性范围、专属性、准确性、精密性、耐用性及定量限。采用建立的方法检测3批供试品重组Omicron BA.4/5-Delta株新冠疫苗的体外相对效力。结果确定解吸附方法为:将疫苗与处理液(1.25 mL 20%二乙醇胺,0.20 mL 10%Triton X-100,8.55 mL PBS)按等体积分数混合,于25℃解离30 min,解吸附率可达95%以上。疫苗参考品在1~26 ng/mL浓度范围内,与A_(450)呈良好的线性关系,线性方程为log(y)=1.447 log(x)-1.643,R^(2)为0.998;可特异性检测疫苗参考品的体外相对效力;90000、50000和20000 ng/mL浓度疫苗参比品检测结果的回收率均在80%~120%范围内;重复性及中间精密性验证相对标准偏差(relative standard deviation,RSD)均<20%;解离条件、检测体系孵育时间和显色时间发生微小变动时,检测结果不受影响;定量限为0.2。批号为J202301002、J202301003、J202301004供试品的体外相对效力分别为1.0,1.0和0.8,RSD为11%。结论建立的用于检测体外相对效力的方法具有良好的准确性、精密性、专属性和耐用性,可用于重组Omicron BA.4/5-Delta株新冠疫苗体外相对效力的检测。展开更多
On November 26,2021,a novel lineage (B.1.1.529) was categorized as the fifth virus of concern (VOC) and named Omicron by World Health Organization (WHO).Patients infected with COVID-19 Omicron variant are reported to ...On November 26,2021,a novel lineage (B.1.1.529) was categorized as the fifth virus of concern (VOC) and named Omicron by World Health Organization (WHO).Patients infected with COVID-19 Omicron variant are reported to have higher transmissibility,lower severity and mortality than those with previous subvariants.In terms of virulence,the Omicron subvariant is weaker than previous strains,with symptoms mostly being fever,running nose and other symptoms mainly seen in upper respiratory tract infections.However,the clinical characteristics of medical staff infected with Omicron variants have rarely been reported before.We conducted a survey in five centers and summarized these profiles to explore the clinical characteristics.展开更多
Background:SARS-CoV-2,first identified in late 2019,has given rise to numerous variants of concern(VOCs),posing a significant threat to human health.The emer-gence of Omicron BA.1.1 towards the end of 2021 led to a pa...Background:SARS-CoV-2,first identified in late 2019,has given rise to numerous variants of concern(VOCs),posing a significant threat to human health.The emer-gence of Omicron BA.1.1 towards the end of 2021 led to a pandemic in early 2022.At present,the lethal mouse model for the study of SARS-CoV-2 needs supplementation,and the alterations in neutrophils and monocytes caused by different strains remain to be elucidated.Methods:Human ACE2 transgenic mice were inoculated with the SARS-CoV-2 proto-type and Omicron BA.1,respectively.The pathogenicity of the two strains was evalu-ated by observing clinical symptoms,viral load and pathology.Complete blood count,immunohistochemistry and flow cytometry were performed to detect the alterations of neutrophils and monocytes caused by the two strains.Results:Our findings revealed that Omicron BA.1 exhibited significantly lower vir-ulence compared to the SARS-CoV-2 prototype in the mouse model.Additionally,we observed a significant increase in the proportion of neutrophils late in infection with the SARS-CoV-2 prototype and Omicron BA.1.We found that the proportion of monocytes increased at first and then decreased.The trends in the changes in the proportions of neutrophils and monocytes induced by the two strains were similar.Conclusion:Our study provides valuable insights into the utility of mouse models for simulating the severe disease of SARS-CoV-2 prototype infection and the milder manifestation associated with Omicron BA.1.SARS-CoV-2 prototype and Omicron BA.1 resulted in similar trends in the changes in neutrophils and monocytes.展开更多
BACKGROUND The emergence of the Omicron variant(B.1.1.529)of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)raised global concerns with its highly transmissible nature.AIM To investigate the genomic,clinic...BACKGROUND The emergence of the Omicron variant(B.1.1.529)of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)raised global concerns with its highly transmissible nature.AIM To investigate the genomic,clinical,and demographic characteristics of Omicron infections within the early outbreak cluster in western part of Sri Lanka.METHODS We analyzed sequence data from January 2022 to April 2022 to understand variant dynamics,clinical presentation,and demographic associations.RESULTS Whole-genome sequencing of 85 nasopharyngeal and throat swab samples collected in western part of Sri Lanka between January and April 2022 identified 70(82.34%)of it as Omicron variants.BA.2 was the most prevalent sub-lineage(57%),followed by BA.1.1(14.20%)and majority of them were from>12 years old individuals.Phylogenetic analysis revealed clustering into four distinct clades(21I,21K,21L,and 21M),suggesting potential differences in transmission chains or evolutionary pressures.CONCLUSION This study found BA.2 to be the predominant Omicron sub-lineage in the western part of Sri Lanka during the first quarter of 2022,aligning with global trends.Phylogenetic analysis revealed diverse introductions and local transmission.Continued genomic surveillance and robust public health measures remain crucial for managing the evolving SARS-CoV-2 landscape.展开更多
目的依据全球最新的分析方法质量源于设计(Analysis Quality by Design,AQbD)和全生命周期理念,建立适用于新型冠状病毒Omicrion XBB.1.5变异株的临床中和抗体和流行病学调查用中和抗体检测方法。方法在已建立的新型冠状病毒原型株中和...目的依据全球最新的分析方法质量源于设计(Analysis Quality by Design,AQbD)和全生命周期理念,建立适用于新型冠状病毒Omicrion XBB.1.5变异株的临床中和抗体和流行病学调查用中和抗体检测方法。方法在已建立的新型冠状病毒原型株中和抗体(CPE法)检测方法的基础上,针对XBB.1.5变异株变更对中和抗体检测方法可能引入的影响因素进行风险评估,对主要风险因素进行条件优化,获得适应XBB.1.5变异株的检测方法,经方法验证明确该方法各项性能指标,并证明方法可满足分析目标概要(Analysis Target Profile,ATP)。结果由XBB.1.5变异株变更引入的主要风险因素为检测细胞、培养基种类和结果判定时间;通过对实验条件优化,最终确定将Vero-E6细胞(DMEM培养基)作为XBB.1.5变异株的最佳培养条件,第5天作为最佳观察时间;经验证得到方法相对准确度和中间精密度的平均相对偏倚为-9.2%~2.9%、几何变异系数(geometric coefficient of variation,GCV)为33.2%~47.1%,满足方法预设ATP,方法误判率低于1.6%。结论依据AQbD和全生命周期的研究理念建立了针对新型冠状病毒XBB.1.5变异株的中和抗体检测方法,经验证该方法满足预设ATP,可用于临床中和抗体和流行病学调查用中和抗体检测。展开更多
文摘目的建立重组Omicron BA.4/5-Delta株新冠疫苗体外相对效力的检测方法,并进行验证,以期为替代体内效力检测奠定基础。方法以人源单克隆抗体GH4作为包被抗体,HRP标记的CB6人源单克隆抗体作为酶标抗体的双抗体夹心ELISA法为基础,确定疫苗解吸附方法;再以该解吸附方法结合双抗体夹心ELISA法建立体外相对效力检测方法。并验证方法的线性范围、专属性、准确性、精密性、耐用性及定量限。采用建立的方法检测3批供试品重组Omicron BA.4/5-Delta株新冠疫苗的体外相对效力。结果确定解吸附方法为:将疫苗与处理液(1.25 mL 20%二乙醇胺,0.20 mL 10%Triton X-100,8.55 mL PBS)按等体积分数混合,于25℃解离30 min,解吸附率可达95%以上。疫苗参考品在1~26 ng/mL浓度范围内,与A_(450)呈良好的线性关系,线性方程为log(y)=1.447 log(x)-1.643,R^(2)为0.998;可特异性检测疫苗参考品的体外相对效力;90000、50000和20000 ng/mL浓度疫苗参比品检测结果的回收率均在80%~120%范围内;重复性及中间精密性验证相对标准偏差(relative standard deviation,RSD)均<20%;解离条件、检测体系孵育时间和显色时间发生微小变动时,检测结果不受影响;定量限为0.2。批号为J202301002、J202301003、J202301004供试品的体外相对效力分别为1.0,1.0和0.8,RSD为11%。结论建立的用于检测体外相对效力的方法具有良好的准确性、精密性、专属性和耐用性,可用于重组Omicron BA.4/5-Delta株新冠疫苗体外相对效力的检测。
文摘On November 26,2021,a novel lineage (B.1.1.529) was categorized as the fifth virus of concern (VOC) and named Omicron by World Health Organization (WHO).Patients infected with COVID-19 Omicron variant are reported to have higher transmissibility,lower severity and mortality than those with previous subvariants.In terms of virulence,the Omicron subvariant is weaker than previous strains,with symptoms mostly being fever,running nose and other symptoms mainly seen in upper respiratory tract infections.However,the clinical characteristics of medical staff infected with Omicron variants have rarely been reported before.We conducted a survey in five centers and summarized these profiles to explore the clinical characteristics.
基金supported by Beijing Natural Science Foundation(Grant No.Z210014)National Natural Science Foundation of China(Grant No.32070543)+1 种基金National Key Research and Development Project of China(Grant No.2022YFC2303404)CAMS Innovation Fund for Medical Sciences(CIFMS)(Grant No.2022-12M-CoV19-002)
文摘Background:SARS-CoV-2,first identified in late 2019,has given rise to numerous variants of concern(VOCs),posing a significant threat to human health.The emer-gence of Omicron BA.1.1 towards the end of 2021 led to a pandemic in early 2022.At present,the lethal mouse model for the study of SARS-CoV-2 needs supplementation,and the alterations in neutrophils and monocytes caused by different strains remain to be elucidated.Methods:Human ACE2 transgenic mice were inoculated with the SARS-CoV-2 proto-type and Omicron BA.1,respectively.The pathogenicity of the two strains was evalu-ated by observing clinical symptoms,viral load and pathology.Complete blood count,immunohistochemistry and flow cytometry were performed to detect the alterations of neutrophils and monocytes caused by the two strains.Results:Our findings revealed that Omicron BA.1 exhibited significantly lower vir-ulence compared to the SARS-CoV-2 prototype in the mouse model.Additionally,we observed a significant increase in the proportion of neutrophils late in infection with the SARS-CoV-2 prototype and Omicron BA.1.We found that the proportion of monocytes increased at first and then decreased.The trends in the changes in the proportions of neutrophils and monocytes induced by the two strains were similar.Conclusion:Our study provides valuable insights into the utility of mouse models for simulating the severe disease of SARS-CoV-2 prototype infection and the milder manifestation associated with Omicron BA.1.SARS-CoV-2 prototype and Omicron BA.1 resulted in similar trends in the changes in neutrophils and monocytes.
文摘BACKGROUND The emergence of the Omicron variant(B.1.1.529)of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)raised global concerns with its highly transmissible nature.AIM To investigate the genomic,clinical,and demographic characteristics of Omicron infections within the early outbreak cluster in western part of Sri Lanka.METHODS We analyzed sequence data from January 2022 to April 2022 to understand variant dynamics,clinical presentation,and demographic associations.RESULTS Whole-genome sequencing of 85 nasopharyngeal and throat swab samples collected in western part of Sri Lanka between January and April 2022 identified 70(82.34%)of it as Omicron variants.BA.2 was the most prevalent sub-lineage(57%),followed by BA.1.1(14.20%)and majority of them were from>12 years old individuals.Phylogenetic analysis revealed clustering into four distinct clades(21I,21K,21L,and 21M),suggesting potential differences in transmission chains or evolutionary pressures.CONCLUSION This study found BA.2 to be the predominant Omicron sub-lineage in the western part of Sri Lanka during the first quarter of 2022,aligning with global trends.Phylogenetic analysis revealed diverse introductions and local transmission.Continued genomic surveillance and robust public health measures remain crucial for managing the evolving SARS-CoV-2 landscape.
文摘目的依据全球最新的分析方法质量源于设计(Analysis Quality by Design,AQbD)和全生命周期理念,建立适用于新型冠状病毒Omicrion XBB.1.5变异株的临床中和抗体和流行病学调查用中和抗体检测方法。方法在已建立的新型冠状病毒原型株中和抗体(CPE法)检测方法的基础上,针对XBB.1.5变异株变更对中和抗体检测方法可能引入的影响因素进行风险评估,对主要风险因素进行条件优化,获得适应XBB.1.5变异株的检测方法,经方法验证明确该方法各项性能指标,并证明方法可满足分析目标概要(Analysis Target Profile,ATP)。结果由XBB.1.5变异株变更引入的主要风险因素为检测细胞、培养基种类和结果判定时间;通过对实验条件优化,最终确定将Vero-E6细胞(DMEM培养基)作为XBB.1.5变异株的最佳培养条件,第5天作为最佳观察时间;经验证得到方法相对准确度和中间精密度的平均相对偏倚为-9.2%~2.9%、几何变异系数(geometric coefficient of variation,GCV)为33.2%~47.1%,满足方法预设ATP,方法误判率低于1.6%。结论依据AQbD和全生命周期的研究理念建立了针对新型冠状病毒XBB.1.5变异株的中和抗体检测方法,经验证该方法满足预设ATP,可用于临床中和抗体和流行病学调查用中和抗体检测。
